TimeTeller GmbH

📍 Hamburg, Germany🗓 Founded 2023👥 6 employees💰 Last funded 2025

At TimeTeller®, our goal is to empower individuals and healthcare professionals with knowledge and tools to optimize health and prevent diseases through understanding and applying the power of circadian rhythms. TimeTeller® profiles your circadian clock using molecular analysis of saliva samples and computational modelling to provide toxicity profiles for optimization of treatment timing. By working with scientists of different research fields and pharmaceutical companies, we want to integrate circadian rhythm-based interventions in pharmacological research and drug development to optimize drug efficacy and diminish toxicity in cancer treatment. Our ultimate goal is to make circadian rhythm-based interventions an integral part of healthcare and enable individuals to live healthier, and more enjoyable lives. Our story: TimeTeller® is a spin-off of the Charité Universitätsmedizin Berlin and builds upon the research of the Circadian Medicine and Systems Biology research group lead by Angela Relógio and on her vision to translate her research findings into a product to benefit the patients. TimeTeller® as a project was initially funded by „Inventors for Health“ (I4H)-program by the Stiftung Charité and later by the Digital Health Accelerator (DHA) from the Berlin Institute of Health (BIH). TimeTeller® was founded, in Hamburg, in March 2023, as a GmbH by Angela Relógio, Benjamin Dose and Ascenion GmbH (the technology transfer partner of Charité). TimeTeller is currently funded by the InnorampUp program of the IFB.

Total investors

Early stage

Mid stage

Late stage

2023

Founded